Jim Tananbaum Introduces Molly He to Foresite Capital for A Better Health Care System

Foresite Capital recently announced its new development on an additional staff member. It is undisputed that for an organization to prosper in business, sometimes new blood with exceptional talent will serve a great purpose. The introduction of Dr. Molly He to Foresite Capital will be a great stride of success to the healthcare sector. She brings to Foresite Capital fifteen years of experience in the medical care industry.

Contribution

According to INC42, the chief executive officer of Foresite Capital, Molly He’s experience will be useful in developing drugs for patients through his company. Dr. He brings to Foresite in –depth scientific research and results on genomics and drug development. Jim Tananbaum added that her excellence in leadership would be valuable to Foresite Capital because the company is looking forward to diversifying its operations and portfolios in transformational ways. She is an alumnus of Illumina. She was the scientist in charge of Illumina’s protein reagent innovation as well as improvements.

Experience

In an article on Biz Journals, before she joined Illumina, Molly was in charge of sciences at the Pacific Biosciences company. In this company, she was in charge of the reagent development in the department of single molecular sequencing chemistry. She spent her first ten years of career in the industry of pharmaceuticals. Her focus was based on the organic base and design of antibody. She worked on cancer-related drugs. Dr. Molly He went to the University of Nankai for a degree in biochemistry and later joined the University of California for a Ph.D. after specializing in protein biophysics.

Jim’s Profile

Jim Tananbaum is a career executive and entrepreneur. He is the chief executive officer of Foresite Capital, a firm that is dedicated to building healthcare leaders by offering financial support. Before joining Foresite Capital, he was a founding partner at Prospect Ventures Partners. With Foresite Capital as his main success story, Jim has been the talk of the Midas list on Forbes. Three times in a row, he has made it through public recognition. Other investments that have contributed to this recognition are Amira Pharmaceuticals, Amerigroup, and Jazz Pharmaceuticals. At Foresite Capital, he has diversified the portfolio of the company to cover patients and physicians. Under his insight, Foresite Capital has partnered with organizations committed to making the health care sector a better service provider.

Click here: https://www.linkedin.com/in/jim-tananbaum-a7562a7/